TICKERNERD
Menu
CGEMCGEMHealthcare · Biotechnology

CGEM Stock Forecast: Cullinan Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$21
−2.05% on the day

The 11 Wall Street analysts covering Cullinan Therapeutics, Inc. hold a median 12-month price target of $30 — +45.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 10 Sept 2026 — in the upper half.

Market cap
$1.3B
Ticker Nerd rank
69 / 100
Median analyst target
$30
Analysts covering
11
Revenue$0.0
Operating income−$57.3M
Net income−$53.7M
Free cash flow−$38.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.2%
1M
+4.8%
YTD
+98.7%
1Y
+210.7%
From 52W high
−10.4%
From 52W low
+257.7%
$6
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGEM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cullinan Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Accruals
83
Value
76
Volatility
73
Growth
60
Quality
52
Size
41
Revisions
40
Issuance
31

Momentum (92): The shares have been drifting up relative to others.

Issuance (31): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CGEM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGEM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26CGEMHigh $42Median $30Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $23Median $30High $42

The green dot is the last close — the median target sits +45.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$30
13 Aug 2026WedbushMaintainsOutperform$39 → $42
29 July 2026BTIGMaintainsBuy$38 → $39
29 July 2026BTIGMaintainsBuy—
11 June 2026WedbushReiteratesOutperform$37
11 June 2026WedbushReiteratesOutperform—
8 June 2026HC Wainwright & Co.ReiteratesBuy$30
8 June 2026HC Wainwright & Co.ReiteratesBuy—
19 May 2026BTIGReiteratesBuy—
8 May 2026WedbushMaintainsOutperform—
4 May 2026BTIGReiteratesBuy—
28 Apr 2026BTIGReiteratesBuy—
28 Apr 2026HC Wainwright & Co.MaintainsBuy—
11 Mar 2026WedbushMaintainsOutperform—
17 Feb 2026CitigroupInitiatesBuy—
2 Feb 2026GuggenheimInitiatesBuy—
8 Jan 2026HC Wainwright & Co.MaintainsBuy—
9 Dec 2025WedbushMaintainsOutperform—
24 Nov 2025BTIGMaintainsBuy$32 → $38
20 Nov 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGEM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CGEM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Cullinan Therapeutics, Inc. returned +210.7% against +17.5% for the S&P 500, dividends included.

CGEM vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Oct 25Jan 26Apr 26Jul 26CGEMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CGEM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
7
Fundamentals

Cullinan Therapeutics, Inc. (CGEM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
9.0×

Cheaper than 60% of US stocks

Price / sales
—
Price / book
4.3×

Cheaper than 24% of US stocks

EV / EBITDA
−4.7×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−50.3%

Higher than 21% of US stocks

Return on assets
−31.4%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cullinan Therapeutics, Inc. (CGEM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cullinan Therapeutics, Inc. has a market value of $1.3B and an enterprise value of $1.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$204.7M.

  • Diluted earnings per share, trailing twelve months: $−3.10.

  • Free cash flow in the twelve months to 30 June 2026: −$159.3M.

  • Shares outstanding: 64.3M.

  • Trailing P/E: 9.0×; forward P/E: −7.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cullinan Therapeutics, Inc. employs 109 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

CGEM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGEMCullinan Therapeutics, Inc.$1.3B
69
IMTXImmatics NV$1.3B
40
DRTSAlpha Tau Medical Ltd.$1.3B
16
OMEROmeros Corp.$1.3B
93
TRAXFirst Tracks Biotherapeutics, Inc.$1.3B
1
VORVor Biopharma, Inc.$1.3B
15
ALMSAlumis, Inc.$1.3B
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cullinan Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGEM news & analysis

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

GlobeNewsWire · 10 Sept 2026positive

Cullinan Therapeutics announced it will host a virtual analyst and investor event to showcase results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC. The data will be presented in Presidential Symposium 2 at the IASLC 2026 World Conference on Lung Cancer on Sunday, September 13, 2026.

Why it matters — The interim analysis of this pivotal Phase 3 trial represents a key clinical milestone for zipalertinib, a core asset that could significantly advance Cullinan's oncology pipeline.

Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset

Seeking Alpha · 26 Aug 2026positive

The article highlights Cullinan Therapeutics' multi-asset portfolio with near-, mid-, and long-term value drivers. It notes zipalertinib's positive Phase 3 results and upcoming regulatory milestones could provide a funding bridge for advancing CGEM's autoimmune and oncology platforms, alongside CLN-049's accelerated regulatory path in AML and CLN-978's early autoimmune data.

Why it matters — CGEM watchers would care because the piece positions the company as having a self-funding path to multiple commercialization opportunities across its pipeline, potentially reducing reliance on external funding.

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Benzinga · 13 Aug 2026positive

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced data from the global REZILIENT3 Phase 3 trial of zipalertinib in certain lung cancer patients.

Why it matters — The Phase 3 trial data provides insights into zipalertinib's potential as a first-line lung cancer treatment, a key development milestone for Cullinan's pipeline.

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 6 Aug 2026neutral

Cullinan Therapeutics issued a corporate update and reported its second quarter 2026 financial results. The company outlined upcoming milestones for its candidate CLN-978, including multi-dose regimen data in rheumatoid arthritis in Q3 2026 and in systemic lupus erythematosus in Q4 2026, with Phase 2 expansion studies expected to begin in early 2027.

Why it matters — CGEM watchers would care because the stated timing for CLN-978 data readouts in RA and SLE, plus the planned Phase 2 expansion, defines the near-term clinical milestones likely to draw attention to the company.

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

GlobeNewsWire · 28 July 2026positive

Cullinan Therapeutics received positive feedback from the FDA following an End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T cell engager for acute myeloid leukemia, and is advancing the program to a potentially registrational Phase 2 study.

Why it matters — This milestone moves CLN-049 closer to potential regulatory approval, which could be significant for Cullinan's pipeline in AML.

FAQ

Frequently asked questions about CGEM stock

What is the CGEM stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Cullinan Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $23 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGEM stock a buy right now?

Of the 11 analysts covering Cullinan Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cullinan Therapeutics, Inc. 69 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGEM?

As at 10 Sept 2026, Cullinan Therapeutics, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will CGEM stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +45.8% from the last close, and Ticker Nerd's factor model ranks Cullinan Therapeutics, Inc. 69 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGEM stock forecast for 2030?

No analyst covering Cullinan Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $42 over the next 12 months.

How has CGEM stock performed over the past year?

Cullinan Therapeutics, Inc. returned +210.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cullinan Therapeutics, Inc. do?

Cullinan Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer.

What is the latest news on CGEM?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer". Cullinan Therapeutics announced it will host a virtual analyst and investor event to showcase results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC. The data will be presented in Presidential Symposium 2 at the IASLC 2026 World Conference on Lung Cancer on Sunday, September 13, 2026.

Company

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The company builds its pipeline around targeted and immune-based approaches, including T cell engagers, bispecific antibodies, monoclonal antibodies, and small-molecule candidates. Its current programs address a range of serious conditions across oncology and immunology, such as non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, systemic lupus erythematosus, and rheumatoid arthritis. Cullinan Therapeutics works to advance differentiated drug candidates through early- and mid-stage clinical development, with a business model centered on discovering high-impact molecules and moving them toward proof of concept. Based in Cambridge, Massachusetts, Cullinan Therapeutics plays a role in the biotechnology market as a developer of precision therapies for diseases with significant unmet medical need.

CEO Mr. Nadim Ahmed M.S. · 109 employees · United States · https://cullinantherapeutics.com